Pharmacokinetics of huperzine A following oral administration to human volunteers

  • Y. X. Li
  • R. Q. Zhang
  • C. R. Li
  • X. H. Jiang


The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20 ∼ 25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5—10 min, and reached the peak concentrations with a Cmax of 2.59±0.37 ng/ml at 58.33±3.89 min (time to reach peak level, Tmax). The area under plasma vs time curve (AUC0−t) and the area under plasma from zero to infinity (AUC0−∞) for huperzine A were found to be 1986.96± 164.57 μg/1-min and 2450.34±233.32 μg/1-min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of α and the β half-life were 21.13±7.28 min and 716.25±130.18 min respectively, and snowed a biphasic profile with rapid distribution followed by a slower elimination rate.

Key words

Huperzine pharmacokinetics human plasma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Liu J.S., Zhu Y.L., Zhou Y.Z., Han Y.Y., Wu F.W., Qi B.F., (1986): The structure of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can. J. Chem. 64, 837–839.CrossRefGoogle Scholar
  2. 2.
    Tang X.C., Han Y.F., Chen X.P., Zhu X.D., (1986): Effects of huperzine A on learning and retrieval processes of discrimination performance in rats. Acta Pharmacol. Sin. 7, 507–511.Google Scholar
  3. 3.
    Tang X.C., De S.P., Sugaya K., Giacobini E., (1989): Effect of huperzine A, a new Cholinesterase inhibitor, on the central cholinergic system of the rat. J. Neur. Res. 24, 276–285.CrossRefGoogle Scholar
  4. 4.
    Tang X.C., (1996): Huperzine A (Shuangyiping): a promising drug for Alzhemimer’s disease. Zhongguo Yaoli Xuebao 17, 481–484.PubMedGoogle Scholar
  5. 5.
    Zangara A., (2003): The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacol. Biochem. Behav. 75, 675–686.CrossRefPubMedGoogle Scholar
  6. 6.
    Qian B.C., Wang M., Zhou Z.F., (1995): Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol. Sin. 16, 396–398.Google Scholar
  7. 7.
    Wang Y.E., Feng J., Lu W.H., (1988): Pharmaceutics of huperaine A in rat and mice. Acta Pharmacol. Sin. 9, 193–197.Google Scholar
  8. 8.
    Wang Y.W., Chu D.F., Gu J.K., (2004): Liquid chromatographic tandem mass spectrometric method for the quantitation of huperzine A in dog plasma. J. Chromatogr. B. 4, 375–378.CrossRefGoogle Scholar
  9. 9.
    Yue P., Zhao Y., Tao T., (2005): Determination of hupezine A in cerebrospinal fluid of rats by HPLC-Fluorescence. Zhongguo Yaoxue Zazhi. 40, 1503–1507.Google Scholar
  10. 10.
    Li C, Du F.F., Yu C, (2004): A sensitive method for the determination of the novelcholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography /tandem mass spectrometry, Rapid Commun. Mass Spectrom. 18, 651–656.CrossRefPubMedGoogle Scholar
  11. 11.
    Li Y.X., Jiang X.H., Lan K., Wang L., (2007): Simple determination of huperzine A in human plasma by liquid chromatographic tandem mass spectrometric method, Biomed. Chromatogr. 21, 15–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Y. X. Li
    • 1
  • R. Q. Zhang
    • 1
  • C. R. Li
    • 1
  • X. H. Jiang
    • 1
  1. 1.West China School of PharmacySichuan UniversitySichuanPeoples’ republic of China

Personalised recommendations